Metal dyshomeostasis and inflammation in Alzheimer's and Parkinson's diseases: Possible impact of environmental exposures

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2013, Pages

  Myhre, Oddvar ^a   Utkilen, Hans ^a   Duale, Nur ^a   Brunborg, Gunnar ^a   Hofer, Tim ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEINS; ANTI-INFLAMMATORY AGENTS; CHRONIC INFLAMMATION; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION ANALYSIS; LYSOSOMAL DEGRADATION; MICROGLIAL ACTIVATIONS; MITOCHONDRIAL DYSFUNCTION;

AMINO ACIDS; ENZYME ACTIVITY; GENE EXPRESSION; GLYCOPROTEINS; IRON; NEURODEGENERATIVE DISEASES; PATHOLOGY;

COPPER;

AMYLOID PRECURSOR PROTEIN; COPPER; FERROPORTIN; HEPCIDIN; IRON; METAL; METALLOTHIONEIN; MICROCYSTIN;

ALZHEIMER DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION; HOMEOSTASIS; HUMAN; INFLAMMATION; PARKINSON DISEASE; REVIEW; RISK FACTOR; UPREGULATION; ANIMAL; GENETICS; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; ENVIRONMENTAL EXPOSURE; HOMEOSTASIS; HUMANS; INFLAMMATION; METALS; PARKINSON DISEASE;

EID: 84877260347     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2013/726954     Document Type: Review

References (209)

1. Blennow K., de Leon M. J., Zetterberg H., Alzheimer's disease. The Lancet 2006 368 9533 387 403 2-s2.0-33746310315 10.1016/S0140-6736(06)69113-7 (Pubitemid 44108123)
2. Huang Y. D., Mucke L., Alzheimer mechanisms and therapeutic strategies. Cell 2012 148 6 1204 1222 10.1016/j.cell.2012.02.040
3. Mullard A., Sting of Alzheimer's failures offset by upcoming prevention trials. Nature Reviews Drug Discovery 2012 11 9 657 660 10.1038/nrd3842
4. Selkoe D. J., Preventing Alzheimer's disease. Science 2012 337 6101 1488 1492 10.1126/science.1228541
5. Reese J. P., Dams J., Winter Y., Balzer-Geldsetzer M., Oertel W. H., Dodel R., Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease. Expert Opinion on Pharmacotherapy 2012 13 7 939 958 10.1517/14656566.2012.677435
6. Costello S., Cockburn M., Bronstein J., Zhang X., Ritz B., Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. American Journal of Epidemiology 2009 169 8 919 926 2-s2.0-63649095770 10.1093/aje/kwp006
7. Ethell D. W., Fei Q., Parkinson-linked genes and toxins that affect neuronal cell death through the Bcl-2 family. Antioxidants & Redox Signaling 2009 11 3 529 540 2-s2.0-58849164675 10.1089/ars.2008.2228
8. Panov A., Dikalov S., Shalbuyeva N., Taylor G., Sherer T., Greenamyre J. T., Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. Journal of Biological Chemistry 2005 280 51 42026 42035 2-s2.0-29644447278 10.1074/jbc.M508628200 (Pubitemid 43023171)
9. Information from the Alzheimer's Association,. 2013, http://www.alz.org/
10. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E. K., Jones P. K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C. S., Petersen R. B., Smith M. A., Oxidative damage is the earliest event in Alzheimer disease. Journal of Neuropathology and Experimental Neurology 2001 60 8 759 767 2-s2.0-0034923434 (Pubitemid 32678256)
11. Perry G., Taddeo M. A., Petersen R. B., Castellani R. J., Harris P. L. R., Siedlak S. L., Cash A. D., Liu Q., Nunomura A., Atwood C. S., Smith M. A., Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. BioMetals 2003 16 1 77 81 2-s2.0-0037355733 10.1023/A:1020731021276 (Pubitemid 36140217)
12. Markesbery W. R., Lovell M. A., Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiology of Aging 1998 19 1 33 36 2-s2.0-0031980065 10.1016/S0197-4580(98)00009-8 (Pubitemid 28167792)
13. Smith M. A., Harris P. L. R., Sayre L. M., Perry G., Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proceedings of the National Academy of Sciences of the United States of America 1997 94 18 9866 9868 2-s2.0-0030885482 10.1073/pnas.94.18.9866 (Pubitemid 27408156)
14. Lassmann H., van Horssen J., Mahad D., Progressive multiple sclerosis: pathology and pathogenesis. Nature Reviews Neurology 2012 8 11 647 656 10.1038/nrneurol.2012.168
15. Lambertsen K. L., Biber K., Finsen B., Inflammatory cytokines in experimental and human stroke. Journal of Cerebral Blood Flow and Metabolism 2012 32 9 1677 1698 10.1038/jcbfm.2012.88
16. Kumar A., Loane D. J., Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. Brain Behavior and Immunity 2012 26 8 1191 1201 10.1016/j.bbi.2012.06.008
17. Muhleisen H., Gehrmann J., Meyermann R., Reactive microglia in Creutzfeldt-Jakob disease. Neuropathology and Applied Neurobiology 1995 21 6 505 517 2-s2.0-0029560332 10.1111/j.1365-2990.1995.tb01097.x (Pubitemid 26029124)
18. Duce J. A., Tsatsanis A., Cater M. A., James S. A., Robb E., Wikhe K., Leong S. L., Perez K., Johanssen T., Greenough M. A., Cho H. H., Galatis D., Moir R. D., Masters C. L., McLean C., Tanzi R. E., Cappai R., Barnham K. J., Ciccotosto G. D., Rogers J. T., Bush A. I., Iron-export ferroxidase activity of β -amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010 142 6 857 867 2-s2.0-77956647381 10.1016/j.cell.2010.08.014
19. Nemeth E., Tuttle M. S., Powelson J., Vaughn M. D., Donovan A., Ward D. M., Ganz T., Kaplan J., Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004 306 5704 2090 2093 2-s2.0-10844258104 10.1126/science.1104742 (Pubitemid 40007660)
20. Wang S. M., Fu L. J., Duan X. L., Crooks D. R., Yu P., Qian Z. M., Di X. J., Li J., Rouault T. A., Chang Y. Z., Role of hepcidin in murine brain iron metabolism. Cellular and Molecular Life Sciences 2010 67 1 123 133 2-s2.0-73749085208 10.1007/s00018-009-0167-3
21. Rogers J. T., Randall J. D., Cahill C. M., Eder P. S., Huang X., Gunshin H., Leiter L., McPhee J., Sarang S. S., Utsuki T., Greig N. H., Lahiri D. K., Tanzi R. E., Bush A. I., Giordano T., Gullans S. R., An iron-responsive element type II in the 52-untranslated region of the Alzheimer's amyloid precursor protein transcript. Journal of Biological Chemistry 2002 277 47 45518 45528 2-s2.0-0347928847 10.1074/jbc.M207435200 (Pubitemid 36159162)
22. Cherny R. A., Legg J. T., McLean C. A., Fairlie D. P., Huang X., Atwood C. S., Beyreuther K., Tanzi R. E., Masters C. L., Bush A. I., Aqueous dissolution of Alzheimer's disease A β amyloid deposits by biometal depletion. Journal of Biological Chemistry 1999 274 33 23223 23228 2-s2.0-0033551782 10.1074/jbc.274.33.23223 (Pubitemid 29388072)
23. Collingwood J. F., Chong R. K. K., Kasama T., Cervera-Gontard L., Dunin-Borkowski R. E., Perry G., P i M., Siedlak S. L., Simpson E. T., Smith M. A., Dobson J., Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer's plaque core material. Journal of Alzheimer's Disease 2008 14 2 235 245 2-s2.0-47849086918 (Pubitemid 352040039)
24. Lovell M. A., Robertson J. D., Teesdale W. J., Campbell J. L., Markesbery W. R., Copper, iron and zinc in Alzheimer's disease senile plaques. Journal of the Neurological Sciences 1998 158 1 47 52 2-s2.0-0032507975 10.1016/S0022-510X(98)00092-6 (Pubitemid 28277534)
25. Barnes D. E., Yaffe K., The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurology 2011 10 9 819 828 10.1016/S1474-4422(11)70072-2
26. Castellano J. M., Kim J., Stewart F. R., Jiang H., DeMattos R. B., Patterson B. W., Fagan A. M., Morris J. C., Mawuenyega K. G., Cruchaga C., Goate A. M., Bales K. R., Paul S. M., Bateman R. J., Holtzman D. M., Human apoE isoforms differentially regulate brain amyloid- β peptide clearance. Science Translational Medicine 2011 3 89 89ra57 10.1126/scitranslmed.3002156
27. Jonsson T., Atwal J. K., Steinberg S., Snaedal J., Jonsson P. V., Bjornsson S., Stefansson H., Sulem P., Gudbjartsson D., Maloney J., Hoyte K., Gustafson A., Liu Y. C., Lu Y. M., Bhangale T., Graham R. R., Huttenlocher J., Bjornsdottir G., Andreassen O. A., Jonsson E. G., Palotie A., Behrens T. W., Magnusson O. T., Kong A., Thorsteinsdottir U., Watts R. J., Stefansson K., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012 488 7409 96 99 10.1038/nature11283
28. Zou K., Gong J. S., Yanagisawa K., Michikawa M., A novel function of monomeric amyloid β -protein serving as an antioxidant molecule against metal-induced oxidative damage. Journal of Neuroscience 2002 22 12 4833 4841 2-s2.0-0037096251 (Pubitemid 37465598)
29. Information from Alzheimer Europe,. 2013, http://www.alzheimer-europe. org/
30. Neafsey E. J., Collins M. A., Moderate alcohol consumption and cognitive risk. Neuropsychiatric Disease and Treatment 2011 7 465 484
31. Arranz S., Chiva-Blanch G., Valderas-Martinez P., Medina-Remon A., Lamuela-Raventos R. M., Estruch R., Wine, beer, alcohol and polyphenols on cardiovascular disease and cancer. Nutrients 2012 4 7 759 781 10.3390/nu4070759
32. Schrag M., Mueller C., Oyoyo U., Smith M. A., Kirsch W. M., Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Progress in Neurobiology 2011 94 3 296 306 2-s2.0-79959395494 10.1016/j.pneurobio.2011.05. 001
33. Noy D., Solomonov I., Sinkevich O., Arad T., Kjaer K., Sagi I., Zinc-amyloid β interactions on a millisecond time-scale stabilize non-fibrillar Alzheimer-related species. Journal of the American Chemical Society 2008 130 4 1376 1383 2-s2.0-38649112930 10.1021/ja076282l (Pubitemid 351171018)
34. Zhou F. T., Chen S. R., Xiong J. P., Li Y. H., Qu L. N., Luteolin reduces zinc-induced tau phosphorylation at Ser262/356 in an ROS-dependent manner in SH-SY5Y cells. Biological Trace Element Research 2012 149 2 273 279 10.1007/s12011-012-9411-z
35. Jack C. R., Knopman D. S., Jagust W. J., Shaw L. M., Aisen P. S., Weiner M. W., Petersen R. C., Trojanowski J. Q., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. The Lancet Neurology 2010 9 1 119 128 2-s2.0-72049130805 10.1016/S1474-4422(09)70299-6
36. Bucossi S., Ventriglia M., Panetta V., Salustri C., Pasqualetti P., Mariani S., Siotto M., Rossini P. M., Squitti R., Copper in alzheimer's disease: a meta-analysis of serum, plasma, and cerebrospinal fluid studies. Journal of Alzheimer's Disease 2011 24 1 175 185 2-s2.0-79955675293 10.3233/JAD-2010-101473
37. Cevenini E., Monti D., Franceschi C., Inflamm-ageing. Current Opinion in Clinical Nutrition and Metabolic Care 2013 16 1 14 20 10.1097/MCO. 0b013e32835ada13
38. Bartzokis G., Lu P. H., Tingus K., Peters D. G., Amar C. P., Tishler T. A., Finn J. P., Villablanca P., Altshuler L. L., Mintz J., Neely E., Connor J. R., Gender and iron genes may modify associations between brain iron and memory in healthy aging. Neuropsychopharmacology 2011 36 7 1375 1384 2-s2.0-79956032674 10.1038/npp.2011.22
39. Hallgren B., Sourander P., The effect of age on the non-haemin iron in the human brain. Journal of Neurochemistry 1958 3 41 51 10.1111/j.1471-4159. 1958.tb12607.x
40. Jane A., Roskams I., Connor J. R., Iron, transferrin, and ferritin in the rat brain during development and aging. Journal of Neurochemistry 1994 63 2 709 716 2-s2.0-0027932255 (Pubitemid 24233709)
41. Xu J., Knutson M. D., Carter C. S., Leeuwenburgh C., Iron accumulation with age, oxidative stress and functional decline. PLoS ONE 2008 3 8 2-s2.0-51449110339 10.1371/journal.pone.0002865 e2865
42. Hofer T., Marzetti E., Xu J., Seo A. Y., Gulec S., Knutson M. D., Leeuwenburgh C., Dupont-Versteegden E. E., Increased iron content and RNA oxidative damage in skeletal muscle with aging and disuse atrophy. Experimental Gerontology 2008 43 6 563 570 2-s2.0-43849083422 10.1016/j.exger.2008.02.007
43. Guralnik J. M., Eisenstaedt R. S., Ferrucci L., Klein H. G., Woodman R. C., Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004 104 8 2263 2268 2-s2.0-4944261763 10.1182/blood-2004-05-1812 (Pubitemid 39331821)
44. Wang Q., Du F., Qian Z. M., Xiao H. G., Zhu L., Wing H. Y., Yang L., Ke Y., Lipopolysaccharide induces a significant increase in expression of iron regulatory hormone hepcidin in the cortex and substantia nigra in rat brain. Endocrinology 2008 149 8 3920 3925 2-s2.0-47949130644 10.1210/en.2007-1626
45. Su Y., Zhang K., Schluesener H. J., Antimicrobial peptides in the brain. Archivum Immunologiae et Therapiae Experimentalis 2010 58 5 365 377 2-s2.0-77956189468 10.1007/s00005-010-0089-7
46. Drakesmith H., Prentice A. M., Hepcidin and the iron-infection axis. Science 2012 338 S768 S772 10.1126/science.1224577
47. Ganz T., Nemeth E., Hepcidin and iron homeostasis. Biochimica et Biophysica Acta 2012 1823 9 1434 1443 10.1016/j.bbamcr.2012.01.014
48. Wu L. J. C., Leenders A. G. M., Cooperman S., Meyron-Holtz E., Smith S., Land W., Tsai R. Y. L., Berger U. V., Sheng Z. H., Rouault T. A., Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier. Brain Research 2004 1001 1-2 108 117 2-s2.0-10744219518 10.1016/j.brainres.2003.10.066 (Pubitemid 38221533)
49. Sun C., Song N., Xie A. M., Xie J. X., Jiang H., High hepcidin level accounts for the nigral iron accumulation in acute peripheral iron intoxication rats. Toxicology Letters 2012 212 3 276 281 10.1016/j.toxlet.2012.05.022
50. Li L., Holscher C., Chen B. B., Zhang Z. F., Liu Y. Z., Hepcidin treatment modulates the expression of divalent metal transporter-1, ceruloplasmin, and ferroportin-1 in the rat cerebral cortex and hippocampus. Biological Trace Element Research 2011 143 3 1581 1593 10.1007/s12011-011-8967-3
51. Besson-Fournier C., Latour C., Kautz L., Bertrand J., Ganz T., Roth M. P., Coppin H., Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood 2012 120 2 431 439 10.1182/blood-2012-02-411470
52. Raha A. A., Zhao J.-W., Stott S., Bomford A., Raha-Chowdhury R., Hepcidin crosses the blood brain barrier during systemic inflammation and after mechanical injury to participate in glial scar formation. submitted to European Journal of Neuroscience, 2013
53. Barnham K. J., McKinstry W. J., Multhaup G., Galatis D., Morton C. J., Curtain C. C., Williamson N. A., White A. R., Hinds M. G., Norton R. S., Beyreuther K., Masters C. L., Parker M. W., Cappai R., Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. Journal of Biological Chemistry 2003 278 19 17401 17407 2-s2.0-0037931743 10.1074/jbc.M300629200 (Pubitemid 36799626)
54. Klomp L. W. J., Farhangrazi Z. S., Dugan L. L., Gitlin J. D., Ceruloplasmin gene expression in the murine central nervous system. Journal of Clinical Investigation 1996 98 1 207 215 2-s2.0-0030036172 10.1172/JCI118768 (Pubitemid 26243838)
55. Scheiber I. F., Schmidt M. M., Dringen R., Zinc prevents the copper-induced damage of cultured astrocytes. Neurochemistry International 2010 57 3 314 322 2-s2.0-77955092432 10.1016/j.neuint.2010.06.010
56. Maynard C. J., Cappai R., Volitakis I., Cherny R. A., White A. R., Beyreuther K., Masters C. L., Bush A. I., Li Q. X., Overexpression of Alzheimer's disease amyloid- β opposes the age-dependent elevations of brain copper and iron. Journal of Biological Chemistry 2002 277 47 44670 44676 2-s2.0-0037160028 10.1074/jbc.M204379200 (Pubitemid 36159056)
57. Klevay L. M., Alzheimer's disease as copper deficiency. Medical Hypotheses 2008 70 4 802 807 2-s2.0-39849096023 10.1016/j.mehy.2007.04.051 (Pubitemid 351318084)
58. Maurer I., Zierz S., Möller H. J., A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiology of Aging 2000 21 3 455 462 2-s2.0-0034612075 10.1016/S0197-4580(00)00112-3 (Pubitemid 30349116)
59. Boll M. C., Alcaraz-Zubeldia M., Montes S., Rios C., Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NOx content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochemical Research 2008 33 9 1717 1723 2-s2.0-48449094910 10.1007/s11064-008-9610-3
60. Gallagher J. J., Finnegan M. E., Grehan B., Dobson J., Collingwood J. F., Lynch M. A., Modest amyloid deposition is associated with iron dysregulation, microglial activation, and oxidative stress. Journal of Alzheimers Disease 2012 28 1 147 161
61. Premkumar D. R. D., Smith M. A., Richey P. L., Petersen R. B., Castellani R., Kutty R. K., Wiggert B., Perry G., Kalaria R. N., Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. Journal of Neurochemistry 1995 65 3 1399 1402 2-s2.0-0029157442
62. Patel J. R., Brewer G. J., Age-related differences in NF B translocation and Bcl-2/Bax ratio caused by TNF α and Abeta42 promote survival in middle-age neurons and death in old neurons. Experimental Neurology 2008 213 1 93 100 2-s2.0-49349097514 10.1016/j.expneurol.2008.05.007
63. Glass C. K., Saijo K., Winner B., Marchetto M. C., Gage F. H., Mechanisms underlying inflammation in neurodegeneration. Cell 2010 140 6 918 934 2-s2.0-77950363010 10.1016/j.cell.2010.02.016
64. Hofer T., Badouard C., Bajak E., Ravanat J. L., Mattsson Å., Cotgreave I. A., Hydrogen peroxide causes greater oxidation in cellular RNA than in DNA. Biological Chemistry 2005 386 4 333 337 2-s2.0-25144486774 10.1515/BC.2005.040 (Pubitemid 41460233)
65. 2 Journal of the Chemical Society, Perkin Transactions 2 2001 2 210 213 2-s2.0-0035763655 10.1039/b006394k (Pubitemid 33757757)
66. Nunomura A., Hofer T., Moreira P. I., Castellani R. J., Smith M. A., Perry G., RNA oxidation in Alzheimer disease and related neurodegenerative disorders. Acta Neuropathologica 2009 118 1 151 166 2-s2.0-67349251839 10.1007/s00401-009-0508-1
67. Nunomura A., Tamaoki T., Motohashi N., Nakamura M., Mckeel D. W., Tabaton M., Lee H. G., Smith M. A., Perry G., Zhu X. W., The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons. Journal of Neuropathology and Experimental Neurology 2012 71 3 233 241 10.1097/NEN. 0b013e318248e614
68. Loeffler D. A., Connor J. R., Juneau P. L., Snyder B. S., Kanaley L., DeMaggio A. J., Nguyen H., Brickman C. M., LeWitt P. A., Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. Journal of Neurochemistry 1995 65 2 710 716 2-s2.0-0029153619
69. Lin D., Lee H. G., Liu Q., Perry G., Smith M. A., Sayre L. M., 4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal. Chemical Research in Toxicology 2005 18 8 1219 1231 2-s2.0-23844448026 10.1021/tx050080q (Pubitemid 41170246)
70. Greilberger J., Fuchs D., Leblhuber F., Greilberger M., Wintersteiger R., Tafeit E., Carbonyl proteins as a clinical marker in Alzheimer's disease and its relation to tryptophan degradation and immune activation. Clinical Laboratory 2010 56 9-10 441 448 2-s2.0-79952113682
71. Smith M. A., Sayre L. M., Anderson V. E., Harris P. L. R., Beal M. F., Kowall N., Perry G., Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4- dinitrophenylhydrazine. Journal of Histochemistry & Cytochemistry 1998 46 6 731 735 2-s2.0-0031776586 10.1177/002215549804600605 (Pubitemid 28272207)
72. Edgar R., Domrachev M., Lash A. E., Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Research 2002 30 1 207 210 2-s2.0-0036081355 10.1093/nar/30.1.207 (Pubitemid 34679544)
73. Liang W. S., Reiman E. M., Valla J., Dunckley T., Beach T. G., Grover A., Niedzielko T. L., Schneider L. E., Mastroeni D., Caselli R., Kukull W., Morris J. C., Hulette C. M., Schmechel D., Rogers J., Stephan D. A., Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proceedings of the National Academy of Sciences of the United States of America 2008 105 11 4441 4446 2-s2.0-41949086089 10.1073/pnas.0709259105 (Pubitemid 351754399)
74. Liang W. S., Dunckley T., Beach T. G., Grover A., Mastroeni D., Walker D. G., Caselli R. J., Kukull W. A., McKeel D., Morris J. C., Hulette C., Schmechel D., Alexander G. E., Reiman E. M., Rogers J., Stephan D. A., Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiological Genomics 2007 28 3 311 322 2-s2.0-34247202571 10.1152/physiolgenomics.00208.2006 (Pubitemid 46708771)
75. Duale N., Lindeman B., Komada M., Olsen A. K., Andreassen A., Soderlund E. J., Brunborg G., Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles. Molecular Cancer 2007 6, article 53 2-s2.0-34748915836 10.1186/1476-4598-6-53 (Pubitemid 47471190)
76. Dysvik B., Jonassen I., J-Express: exploring gene expression data using Java. Bioinformatics 2001 17 4 369 370 2-s2.0-0035021690 10.1093/bioinformatics/ 17.4.369 (Pubitemid 32421932)
77. Saeed A. I., Bhagabati N. K., Braisted J. C., Liang W., Sharov V., Howe E. A., Li J., Thiagarajan M., White J. A., Quackenbush J., TM4 microarray software suite. Methods in Enzymology 2006 411 134 193 2-s2.0-33747894577 10.1016/S0076-6879(06)11009-5 (Pubitemid 44291425)
78. Tusher V. G., Tibshirani R., Chu G., Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America 2001 98 9 5116 5121 2-s2.0-0035942271 10.1073/pnas.091062498 (Pubitemid 32397092)
79. Li G. Y., Cai F., Yan W., Li C. R., Wang J. H., A proteomic analysis of MCLR-induced neurotoxicity: implications for Alzheimer's disease. Toxicological Sciences 2012 127 2 485 495 10.1093/toxsci/kfs114
80. Chorus I., Bartram J., Toxic Cyanobacteria in Water. A Guide to Their Public Health Consequences, monitoring and Management 1999 New York, NY, USA WHO Publication E & FN SPON
81. Cox P. A., Banack S. A., Murch S. J., Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proceedings of the National Academy of Sciences of the United States of America 2003 100 23 13380 13383 2-s2.0-0345255588 10.1073/pnas.2235808100 (Pubitemid 37444750)
82. Sivonen K., Jones G., Chorus I., Bartram J., Cyanobacterial toxins. Toxic Cyanobacteria in Water. A Guide to Their Public Health Consequences, monitoring and Management 1999 New York, NY, USA WHO Publication E & FN SPON 41 109
83. Feurstein D., Stemmer K., Kleinteich J., Speicher T., Dietrich D. R., Microcystin congener- and concentration-dependent induction of murine neuron apoptosis and neurite degeneration. Toxicological Sciences 2011 124 2 424 431 10.1093/toxsci/kfr243
84. Briand J. F., Jacquet S., Bernard C., Humbert J. F., Health hazards for terrestrial vertebrates from toxic cyanobacteria in surface water ecosystems. Veterinary Research 2003 34 4 361 377 2-s2.0-0141626442 10.1051/vetres:2003019 (Pubitemid 37121280)
85. Stewart I., Seawright A. A., Shaw G. R., Cyanobacterial poisoning in livestock, wild mammals and birds-an overview. Advances in Experimental Medicine and Biology 2008 619 613 637 2-s2.0-45549099258 10.1007/978-0-387-75865-7-28
86. Pouria S., De Andrade A., Barbosa J., Cavalcanti R. L., Barreto V. T. S., Ward C. J., Preiser W., Poon G. K., Neild G. H., Codd G. A., Fatal microcystin intoxication in haemodialysis unit in Caruaru, Brazil. The Lancet 1998 352 9121 21 26 2-s2.0-0002357912 10.1016/S0140-6736(97)12285-1 (Pubitemid 28306561)
87. Cox P. A., Banack S. A., Murch S. J., Rasmussen U., Tien G., Bidigare R. R., Metcalf J. S., Morrison L. F., Codd G. A., Bergman B., Diverse taxa of cyanobacteria produce β -N-methylamino-L-alanine, a neurotoxic amino acid. Proceedings of the National Academy of Sciences of the United States of America 2005 102 14 5074 5078 2-s2.0-20144388052 10.1073/pnas.0501526102
88. Pablo J., Banack S. A., Cox P. A., Johnson T. E., Papapetropoulos S., Bradley W. G., Buck A., Mash D. C., Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurologica Scandinavica 2009 120 4 216 225 2-s2.0-70349229843 10.1111/j.1600-0404.2008.01150.x
89. Dietrich D. R., Fischer A., Michel C., Hoeger S., Toxin mixture in cyanobacterial blooms-a critical comparison of reality with current procedures employed in human health risk assessment. Advances in Experimental Medicine and Biology 2008 619 885 912 2-s2.0-45549087136 10.1007/978-0-387-75865-7-39
90. Meriluoto J. A. O., Nygard S. E., Dahlem A. M., Eriksson J. E., Synthesis, organotropism and hepatocellular uptake of two tritium-labeled epimers of dihydromicrocystin-LR, a cyanobacterial peptide toxin analog. Toxicon 1990 28 12 1439 1446 2-s2.0-0025188759 10.1016/0041-0101(90)90157-3 (Pubitemid 20383754)
91. Cherny R. A., Atwood C. S., Xilinas M. E., Gray D. N., Jones W. D., McLean C. A., Barnham K. J., Volitakis I., Fraser F. W., Kim Y. S., Huang X., Goldstein L. E., Moir R. D., Lim J. T., Beyreuther K., Zheng H., Tanzi R. E., Masters C. L., Bush A. I., Treatment with a copper-zinc chelator markedly and rapidly inhibits β -amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001 30 3 665 676 2-s2.0-0034964390 10.1016/S0896-6273(01)00317-8 (Pubitemid 32607332)
92. Kupershmidt L., Amit T., Bar-Am O., Youdim M. B. H., Weinreb O., The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. Antioxidants & Redox Signaling 2012 17 6 860 877 10.1089/ars.2011.4279
93. Hider R. C., Roy S., Ma Y. M., Le Kong X., Preston J., The potential application of iron chelators for the treatment of neurodegenerative diseases. Metallomics 2011 3 3 239 249 2-s2.0-79952498467 10.1039/c0mt00087f
94. Mandel S., Amit T., Reznichenko L., Weinreb O., Youdim M. B. H., Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Molecular Nutrition & Food Research 2006 50 2 229 234 2-s2.0-33644660982 10.1002/mnfr.200500156 (Pubitemid 43325663)
95. Dwyer B. E., Zacharski L. R., Balestra D. J., Lerner A. J., Perry G., Zhu X., Smith M. A., Getting the iron out: phlebotomy for Alzheimer's disease? Medical Hypotheses 2009 72 5 504 509 2-s2.0-61349180687 10.1016/j.mehy.2008.12. 029
96. McLachlan D. R. C., Dalton A. J., Kruck T. P. A., Bell M. Y., Smith W. L., Kalow W., Andrews D. F., Intramuscular desferrioxamine in patients with Alzheimer's disease. The Lancet 1991 337 8753 1304 1308 2-s2.0-0025726462 10.1016/0140-6736(91)92978-B
97. Miyajima H., Takahashi Y., Kamata T., Shimizu H., Sakai N., Gitlin J. D., Use of desferrioxamine in the treatment of aceruloplasminemia. Annals of Neurology 1997 41 3 404 407 2-s2.0-0031058837 10.1002/ana.410410318 (Pubitemid 27114054)
98. Molina-Holgado F., Gaeta A., Francis P. T., Williams R. J., Hider R. C., Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. Journal of Neurochemistry 2008 105 6 2466 2476 2-s2.0-44649108912 10.1111/j.1471-4159.2008.05332.x (Pubitemid 351782272)
99. Ma Y. M., Roy S., Kong X. L., Chen Y. L., Liu D. Y., Hider R. C., Design and synthesis of fluorinated iron chelators for metabolic study and brain uptake. Journal of Medicinal Chemistry 2012 55 5 2185 2195 10.1021/jm201475u
100. Ritchie C. W., Bush A. I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q. X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R. E., Masters C. L., Metal-protein attenuation with lodochlorhydroxyquin (clioquinol) targeting A β amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Archives of Neurology 2003 60 12 1685 1691 2-s2.0-10744224267 10.1001/archneur.60.12.1685 (Pubitemid 37521621)
101. Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., Masters C. L., Targum S., Bush A. I., Murdoch R., Wilson J., Ritchie C. W., Safety, efficacy, and biomarker findings of PBT2 in targeting A β as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. The Lancet Neurology 2008 7 9 779 786 2-s2.0-48949098573 10.1016/S1474-4422(08)70167-4
102. Moret V., Laras Y., Pietrancosta N., Garino C., Quélévera G., Rolland A., Mallet B., Norreel J. C., Kraus J. L., 1,1′-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution. Bioorganic and Medicinal Chemistry Letters 2006 16 12 3298 3301 2-s2.0-33646490404 10.1016/j.bmcl.2006.03.026
103. Antequera D., Bolos M., Spuch C., Pascual C., Ferrer I., Fernandez-Bachiller M. I., Rodriguez-Franco M. I., Carro E., Effects of a tacrine-8-hydroxyquinoline hybrid (IQM-622) on A beta accumulation and cell death: involvement in hippocampal neuronal loss in Alzheimer's disease. Neurobiology of Disease 2012 46 3 682 691 10.1016/j.nbd.2012.03.009
104. Lee J. Y., Friedman J. E., Angel I., Kozak A., Koh J. Y., The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human β -amyloid precursor protein transgenic mice. Neurobiology of Aging 2004 25 10 1315 1321 2-s2.0-4644238758 10.1016/j.neurobiolaging.2004.01.005 (Pubitemid 39299169)
105. Petri S., Calingasan N. Y., Alsaied O. A., Wille E., Kiaei M., Friedman J. E., Baranova O., Chavez J. C., Beal M. F., The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry 2007 102 3 991 1000 2-s2.0-34447298861 10.1111/j.1471-4159.2007.04604.x (Pubitemid 47057303)
106. Squitti R., Rossini P. M., Cassetta E., Moffa F., Pasqualetti P., Cortesi M., Colloca A., Rossi L., Finazzi-Agro A., D-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. European Journal of Clinical Investigation 2002 32 1 51 59 2-s2.0-0037003044 10.1046/j.1365-2362.2002.00933.x (Pubitemid 36228383)
107. Cui Z., Lockman P. R., Atwood C. S., Hsu C. H., Gupte A., Allen D. D., Mumper R. J., Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. European Journal of Pharmaceutics and Biopharmaceutics 2005 59 2 263 272 2-s2.0-12344251715 10.1016/j.ejpb.2004. 07.009 (Pubitemid 40127583)
108. Essa M. M., Vijayan R. K., Castellano-Gonzalez G., Memon M. A., Braidy N., Guillemin G. J., Neuroprotective effect of natural products against Alzheimer's disease. Neurochemical Research 2012 37 9 1829 1842
109. Lovell M. A., Xiong S., Lyubartseva G., Markesbery W. R., Organoselenium (Sel-Plex diet) decreases amyloid burden and RNA and DNA oxidative damage in APP/PS1 mice. Free Radical Biology and Medicine 2009 46 11 1527 1533 2-s2.0-67349196022 10.1016/j.freeradbiomed.2009.03.008
110. Obulesu M., Dowlathabad M. R., Bramhachari P. V., Carotenoids and Alzheimer's disease: an insight into therapeutic role of retinoids in animal models. Neurochemistry International 2011 59 5 535 541 10.1016/j.neuint.2011.04. 004
111. Loef M., Schrauzer G. N., Walach H., Selenium and Alzheimer's disease: a systematic review. Journal of Alzheimers Disease 2011 26 1 81 104
112. Jiao Y., Wilkinson J., Christine Pietsch E., Buss J. L., Wang W., Planalp R., Torti F. M., Torti S. V., Iron chelation in the biological activity of curcumin. Free Radical Biology and Medicine 2006 40 7 1152 1160 2-s2.0-33644988713 10.1016/j.freeradbiomed.2005.11.003
113. Lim G. P., Chu T., Yang F., Beech W., Frautschy S. A., Cole G. M., The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. Journal of Neuroscience 2001 21 21 8370 8377 2-s2.0-0035503597 (Pubitemid 33051435)
114. Liu L. X., Chen W. F., Xie J. X., Wong M. S., Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Neuroscience Research 2008 60 2 156 161 2-s2.0-38649088871 10.1016/j.neures. 2007.10.005 (Pubitemid 351173378)
115. Jang S., Kelley K. W., Johnson R. W., Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proceedings of the National Academy of Sciences of the United States of America 2008 105 21 7534 7539 2-s2.0-44949125522 10.1073/pnas.0802865105 (Pubitemid 351830053)
116. Cao C. H., Loewensteine D. A., Lin X. Y., Zhang C., Wang L., Duara R., Wu Y. G., Giannini A., Bai G., Cai J. F., Greig M., Schofield E., Ashok R., Small B., Potter H., Arendash G. W., High blood caffeine levels in MCI linked to lack of progression to dementia. Journal of Alzheimers Disease 2012 30 3 559 572 10.3233/JAD-2012-111781
117. Costa J., Lunet N., Santos C., Santos J., Vaz-Carneiro A., Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studiess. Journal of Alzheimer's Disease 2010 20 1 S221 S238 2-s2.0-77956224302 10.3233/JAD-2010-091525
118. Poewe W., Non-motor symptoms in Parkinson's disease. European Journal of Neurology 2008 15 1 14 20 2-s2.0-41049106214 10.1111/j.1468-1331.2008.02056.x (Pubitemid 351421304)
119. Langston J. W., Parkinson's disease: current and future challenges. NeuroToxicology 2002 23 4-5 443 450 2-s2.0-0036776975 10.1016/S0161-813X(02) 00098-0 (Pubitemid 36527664)
120. Olanow C. W., Tatton W. G., Etiology and pathogenesis of Parkinson's disease. Annual Review of Neuroscience 1999 22 123 144 2-s2.0-0032936755 10.1146/annurev.neuro.22.1.123 (Pubitemid 29144883)
121. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K., Stages in the development of Parkinson's disease-related pathology. Cell and Tissue Research 2004 318 1 121 134 2-s2.0-5444255434 10.1007/s00441-004-0956-9 (Pubitemid 39362633)
122. Lesage S., Brice A., Parkinson's disease: from monogenic forms to genetic susceptibility factors. Human Molecular Genetics 2009 18 1 R48 R59 2-s2.0-63149090431 10.1093/hmg/ddp012
123. Kuopio A. M., Marttila R. J., Helenius H., Rinne U. K., Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology 1999 52 2 302 308 2-s2.0-0033556361 10.1212/WNL.52.2.302 (Pubitemid 29059056)
124. Tanner C. M., Ottman R., Goldman S. M., Ellenberg J., Chan P., Mayeux R., Langston J. W., Parkinson disease in twins: an etiologic study. Journal of the American Medical Association 1999 281 4 341 346 2-s2.0-0033608187 10.1001/jama.281.4.341 (Pubitemid 29061038)
125. Abou-Sleiman P. M., Muqit M. M. K., Wood N. W., Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nature Reviews Neuroscience 2006 7 3 207 219 2-s2.0-33644543761 10.1038/nrn1868 (Pubitemid 43292466)
126. Mandel S., Weinreb O., Amit T., Youdim M. B. H., Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Research Reviews 2005 48 2 379 387 2-s2.0-17844406615 10.1016/j.brainresrev.2004.12.027 (Pubitemid 40590050)
127. Greene J. G., Dingledine R., Greenamyre J. T., Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiology of Disease 2005 18 1 19 31 2-s2.0-11844262742 10.1016/j.nbd.2004.10.003 (Pubitemid 40092894)
128. Gu M., Cooper J. M., Taanman J. W., Schapira A. H. V., Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Annals of Neurology 1998 44 2 177 186 2-s2.0-0031859395 10.1002/ana.410440207 (Pubitemid 28374105)
129. Jenner P., Oxidative stress in Parkinson's disease. Annals of Neurology 2003 53 3 S26 S38 2-s2.0-0037378026 10.1002/ana.10483 (Pubitemid 36368560)
130. 2-microglobulin levels are elevated in the striatum in Parkinson's disease. Journal of Neural Transmission. Parkinson's Disease and Dementia Section 1995 9 1 87 92 2-s2.0-0028986551 10.1007/BF02252965
131. McGeer P. L., Yasojima K., McGeer E. G., Inflammation in Parkinson's disease. Advances in neurology 2001 86 83 89 2-s2.0-0035236738
132. Moon M., Kim H. G., Hwang L., Seo J. H., Kim S., Hwang S., Kim S., Lee D., Chung H., Oh M. S., Lee K. T., Park S., Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation. Neurotoxicity Research 2009 15 4 332 347 2-s2.0-70449527787 10.1007/s12640-009-9037-x
133. Whitton P. S., Inflammation as a causative factor in the aetiology of Parkinson's disease. British Journal of Pharmacology 2007 150 8 963 976 2-s2.0-34247366072 10.1038/sj.bjp.0707167 (Pubitemid 46628616)
134. Zhou Y., Zhang Y. X., Li J. Q., Lv F. Y., Zhao Y. M., Duan D. Y., Xu Q. Y., A comprehensive study on long-term injury to nigral dopaminergic neurons following intracerebroventricular injection of lipopolysaccharide in rats. Journal of Neurochemistry 2012 123 5 771 780 10.1111/jnc.12010
135. Hunter R. L., Cheng B., Choi D. Y., Liu M., Liu S., Cass W. A., Bing G., Intrastriatal lipopolysaccharide injection induces Parkinsonism in C57/B6 mice. Journal of Neuroscience Research 2009 87 8 1913 1921 2-s2.0-66049127133 10.1002/jnr.22012
136. Wu X. F., Block M. L., Zhang W., Qin L., Wilson B., Zhang W. Q., Veronesi B., Hong J. S., The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxidants & Redox Signaling 2005 7 5-6 654 661 2-s2.0-16344386871 10.1089/ars.2005.7.654 (Pubitemid 40563204)
137. Arif I. A., Khan H. A., Environmental toxins and Parkinson's disease: putative roles of impaired electron transport chain and oxidative stress. Toxicology and Industrial Health 2010 26 2 121 128 2-s2.0-77951909047 10.1177/0748233710362382
138. Gao H. M., Liu B., Hong J. S., Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. Journal of Neuroscience 2003 23 15 6181 6187 2-s2.0-0038044029 (Pubitemid 36875618)
139. Mao H., Fang X., Floyd K. M., Polcz J. E., Zhang P., Liu B., Induction of microglial reactive oxygen species production by the organochlorinated pesticide dieldrin. Brain Research 2007 1186 1 267 274 2-s2.0-37649009509 10.1016/j.brainres.2007.10.020
140. Block M. L., Wu X., Pei Z., Li G., Wang T., Qin L., Wilson B., Yang J., Hong J. S., Veronesi B., Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase. The FASEB Journal 2004 18 13 1618 1620 2-s2.0-9444284332 10.1096/fj.04-1945fje (Pubitemid 39561652)
141. Mao H., Liu B., Synergistic microglial reactive oxygen species generation induced by pesticides lindane and dieldrin. NeuroReport 2008 19 13 1317 1320 2-s2.0-52649126841 10.1097/WNR.0b013e32830b3677
142. Domico L. M., Cooper K. R., Bernard L. P., Zeevalk G. D., Reactive oxygen species generation by the ethylene-bis-dithiocarbamate (EBDC) fungicide mancozeb and its contribution to neuronal toxicity in mesencephalic cells. NeuroToxicology 2007 28 6 1079 1091 2-s2.0-35648932406 10.1016/j.neuro.2007.04. 008 (Pubitemid 350026582)
143. Akopian G., Crawford C., Petzinger G., Jakowec M. W., Walsh J. P., Brief mitochondrial inhibition causes lasting changes in motor behavior and corticostriatal synaptic physiology in the Fischer 344 rat. Neuroscience 2012 215 149 159 10.1016/j.neuroscience.2012.04.060
144. Brouillet E., Jacquard C., Bizat N., Blum D., 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. Journal of Neurochemistry 2005 95 6 1521 1540 2-s2.0-29144468251 10.1111/j.1471-4159.2005.03515.x (Pubitemid 41804051)
145. Sauerbeck A., Hunter R., Bing G. Y., Sullivan P. G., Traumatic brain injury and trichloroethylene exposure interact and produce functional, histological, and mitochondrial deficits. Experimental Neurology 2012 234 1 85 94 10.1016/j.expneurol.2011.12.012
146. Dhillon A. S., Tarbutton G. L., Levin J. L., Plotkin G. M., Lowry L. K., Nalbone J. T., Shepherd S., Pesticide/environmental exposures and Parkinson's disease in East Texas. Journal of Agromedicine 2008 13 1 37 48 2-s2.0-58149289881 10.1080/10599240801986215
147. Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L., Kortsha G. X., Brown G. G., Richardson R. J., Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. NeuroToxicology 1999 20 2-3 239 248 2-s2.0-0033037034 (Pubitemid 29268568)
148. Lucchini R. G., Albini E., Benedetti L., Borghesi S., Coccaglio R., Malara E. C., Parrinello G., Garattini S., Resola S., Alessio L., High prevalence of Parkinsonian disorders associated to manganese exposure in the vicinities of ferroalloy industries. American Journal of Industrial Medicine 2007 50 11 788 800 2-s2.0-35649023123 10.1002/ajim.20494 (Pubitemid 350036017)
149. Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L., Kortsha G. X., Brown G. G., Richardson R. J., Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997 48 3 650 658 2-s2.0-0030940439 10.1212/WNL.48.3.650 (Pubitemid 27120101)
150. Calderon-Garciduenas L., D'Angiulli A., Kulesza R. J., Air pollution is associated with brainstem auditory nuclei pathology and delayed brainstem auditory evoked potentials. International Journal of Developmental Neuroscience 2011 29 4 365 375 2-s2.0-79955786502 10.1016/j.ijdevneu.2011.03.007
151. Ross C. A., Poirier M. A., Protein aggregation and neurodegenerative disease. Nature Medicine 2004 10 7 S10 S17 2-s2.0-3142514201 10.1038/nm1066 (Pubitemid 38901862)
152. Braak H., Braak E., Cognitive impairment in Parkinson's disease: amyloid plagues, neurofibrillary tangles, and neuropil threads in the cerebral cortex. Journal of Neural Transmission. Parkinson's Disease and Dementia Section 1990 2 1 45 57 2-s2.0-0025276828 10.1007/BF02251245 (Pubitemid 20215381)
153. Galasko D., Hansen L. A., Katzman R., Wiederholt W., Masliah E., Terry R., Hill L. R., Lessin P., Thal L. J., Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Archives of Neurology 1994 51 9 888 895 2-s2.0-0027980815 10.1001/archneur.1994.00540210060013 (Pubitemid 24286043)
154. Stefanova N., Reindl M., Neumann M., Kahle P. J., Poewe W., Wenning G. K., Microglial activation mediates neurodegeneration related to oligodendroglial α -synucleinopathy: implications for multiple system atrophy. Movement Disorders 2007 22 15 2196 2203 2-s2.0-36949032824 10.1002/mds.21671
155. Zhang W., Wang T., Pei Z., Miller D. S., Wu X., Block M. L., Wilson B., Zhang W., Zhou Y., Hong J. S., Zhang J., Aggregated α -synuclein activates microglia: a process leading to disease progression in Parkinson's disease. The FASEB Journal 2005 19 6 533 542 2-s2.0-20144389524 10.1096/fj.04-2751com (Pubitemid 40471244)
156. Gao H. M., Kotzbauer P. T., Uryu K., Leight S., Trojanowski J. Q., Lee V. M. Y., Neuroinflammation and oxidation/nitration of α -synuclein linked to dopaminergic neurodegeneration. Journal of Neuroscience 2008 28 30 7687 7698 2-s2.0-50549085408 10.1523/JNEUROSCI.0143-07.2008
157. Leonard B. E., Changes in the immune system in depression and dementia: causal or co-incidental effects? International Journal of Developmental Neuroscience 2001 19 3 305 312 2-s2.0-0035030335 10.1016/S0736-5748(01)00014-4 (Pubitemid 32405350)
158. Maccioni R. B., Rojo L. E., Fernández J. A., Kuljis R. O., The role of neuroimmunomodulation in Alzheimer's disease. Annals of the New York Academy of Sciences 2009 1153 240 246 2-s2.0-60349132064 10.1111/j.1749-6632. 2008.03972.x
159. Manelli A. M., Puttfarcken P. S., β -Amyloid-induced toxicity in rat hippocampal cells: in vitro evidence for the involvement of free radicals. Brain Research Bulletin 1995 38 6 569 576 2-s2.0-0028971093 10.1016/0361- 9230(95)02034-X (Pubitemid 3007073)
160. Hochstrasser T., Hohsfield L. A., Sperner-Unterweger B., Humpel C., β -Amyloid induced effects on cholinergic, serotonergic, and dopaminergic neurons is differentially counteracted by anti-inflammatory drugs. Journal of Neuroscience Research 2013 91 1 83 94
161. Shi M., Zhang J., CSF α -synuclein, tau, and amyloid β in Parkinson's disease. The Lancet Neurology 2011 10 8 681 2-s2.0-79960353168 10.1016/S1474-4422(11)70130-2
162. Tremblay M. E., Majewska A. K., A role for microglia in synaptic plasticity? Communicative & Integrative Biology 2011 4 2 220 222 10.4161/cib.4.2.14506
163. Neumann H., Kotter M. R., Franklin R. J. M., Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 2009 132 2 288 295 2-s2.0-60149098421 10.1093/brain/awn109
164. Rivest S., The promise of anti-inflammatory therapies for CNS injuries and diseases. Expert Review of Neurotherapeutics 2011 11 6 783 786 2-s2.0-79958281908 10.1586/ern.11.64
165. Block M. L., Zecca L., Hong J. S., Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience 2007 8 1 57 69 2-s2.0-33845768784 10.1038/nrn2038 (Pubitemid 46011999)
166. Lawson L. J., Perry V. H., Dri P., Gordon S., Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990 39 1 151 170 2-s2.0-0025220976 10.1016/0306-4522(90)90229-W
167. Mittelbronn M., Dietz K., Schluesener H. J., Meyermann R., Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathologica 2001 101 3 249 255 2-s2.0-0035105538 (Pubitemid 32219759)
168. Jurgens H. A., Johnson R. W., Dysregulated neuronal-microglial cross-talk during aging, stress and inflammation. Experimental Neurology 2012 233 1 40 48 2-s2.0-78650556025 10.1016/j.expneurol.2010.11.014
169. Sheffield L. G., Berman N. E. J., Microglial expression of MHC class II increases in normal aging of nonhuman primates. Neurobiology of Aging 1998 19 1 47 55 2-s2.0-0031960498 10.1016/S0197-4580(97)00168-1 (Pubitemid 28167795)
170. Banati R. B., Gehrmann J., Schubert P., Kreutzberg G. W., Cytotoxicity of microglia. Glia 1993 7 1 111 118 2-s2.0-0027351431 10.1002/glia.440070117
171. Gehrmann J., Matsumoto Y., Kreutzberg G. W., Microglia: intrinsic immuneffector cell of the brain. Brain Research Reviews 1995 20 3 269 287 2-s2.0-0029076362 10.1016/0165-0173(94)00015-H
172. Hopkins S. J., Rothwell N. J., Cytokines and the nervous system I: expression and recognition. Trends in Neurosciences 1995 18 2 83 88 2-s2.0-0028800715 10.1016/0166-2236(95)93881-W
173. Perry V. H., Nicoll J. A. R., Holmes C., Microglia in neurodegenerative disease. Nature Reviews Neurology 2010 6 4 193 201 2-s2.0-77950858637 10.1038/nrneurol.2010.17
174. Kim Y. S., Kim S. S., Cho J. J., Choi D. H., Hwang O., Shin D. H., Chun H. S., Beal M. F., Joh T. H., Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. Journal of Neuroscience 2005 25 14 3701 3711 2-s2.0-17044432238 10.1523/JNEUROSCI.4346-04. 2005
175. Kim Y. S., Joh T. H., Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Experimental and Molecular Medicine 2006 38 4 333 347 2-s2.0-33748447845 10.1038/emm.2006.40
176. Kim Y. S., Choi D. H., Block M. L., Lorenzl S., Yang L., Kim Y. J., Sugama S., Cho B. P., Hwang O., Browne S. E., Kim S. Y., Hong J. S., Beal M. F., Joh T. H., A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. The FASEB Journal 2007 21 1 179 187 2-s2.0-33845977715 10.1096/fj.06-5865com (Pubitemid 46052555)
177. Mander P. K., Jekabsone A., Brown G. C., Microglia proliferation is regulated by hydrogen peroxide from NADPH oxidase. Journal of Immunology 2006 176 2 1046 1052 2-s2.0-30744455267 (Pubitemid 43099705)
178. Park K. W., Baik H. H., Jin B. K., Interleukin-4-induced oxidative stress via microglial NADPH oxidase contributes to the death of hippocampal neurons in vivo. Current Aging Science 2008 1 3 192 201 2-s2.0-77649213747 10.2174/1874609810801030192
179. Park K. W., Baik H. H., Jin B. K., IL-13-induced oxidative stress via microglial NADPH oxidase contributes to death of hippocampal neurons in vivo. Journal of Immunology 2009 183 7 4666 4674 2-s2.0-70449723396 10.4049/jimmunol.0803392
180. Wilkinson B. L., Landreth G. E., The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. Journal of Neuroinflammation 2006 3, article 30 2-s2.0-33751192706 10.1186/1742-2094-3-30 (Pubitemid 44774182)
181. Uversky V. N., Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell and Tissue Research 2004 318 1 225 241 2-s2.0-5444255433 10.1007/s00441-004-0937-z (Pubitemid 39362642)
182. Della Bianca V., Dusi S., Bianchini E., Dal Pra I., Rossi F., β -Amyloid activates the O2·̄ forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. Journal of Biological Chemistry 1999 274 22 15493 15499 2-s2.0-0032983334 10.1074/jbc.274.22.15493 (Pubitemid 29254916)
183. Sankarapandi S., Zweier J. L., Mukherjee G., Quinn M. T., Huso D. L., Measurement and characterization of superoxide generation in microglial cells: evidence for an NADPH oxidase-dependent pathway. Archives of Biochemistry and Biophysics 1998 353 2 312 321 2-s2.0-0032524692 10.1006/abbi.1998.0658 (Pubitemid 28373015)
184. Loane D. J., Byrnes K. R., Role of microglia in neurotrauma. Neurotherapeutics 2010 7 4 366 377 2-s2.0-77957086962 10.1016/j.nurt.2010.07.002
185. +-induced neurodegeneration. Neuromolecular Medicine 2012 14 4 317 327 10.1007/s12017-012-8189-7
186. Purisai M. G., McCormack A. L., Cumine S., Li J., Isla M. Z., Di Monte D. A., Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiology of Disease 2007 25 2 392 400 2-s2.0-33846308531 10.1016/j.nbd.2006.10.008 (Pubitemid 46124019)
187. Mangano E. N., Litteljohn D., So R., Nelson E., Peters S., Bethune C., Bobyn J., Hayley S., Interferon- γ plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways. Neurobiology of Aging 2012 33 7 1411 1426 2-s2.0-79953754893 10.1016/j.neurobiolaging.2011. 02.016
188. Ferraz H. B., Bertolucci P. H. F., Pereira J. S., Lima J. G. C., Andrade L. A. F., Chronic exposure to the fungicide maneb may produce symptoms and signs of CNS manganese intoxication. Neurology 1988 38 4 550 553 2-s2.0-0023882918 10.1212/WNL.38.4.550
189. Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L., Richardson R. J., The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998 50 5 1346 1350 2-s2.0-0031843721 10.1212/WNL.50.5.1346 (Pubitemid 28240350)
190. Liou H. H., Tsai M. C., Chen C. J., Jeng J. S., Chang Y. C., Chen S. Y., Chen R. C., Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997 48 6 1583 1588 2-s2.0-0030878320 10.1212/WNL.48.6.1583
191. Stankiewicz J., Panter S. S., Neema M., Arora A., Batt C. E., Bakshi R., Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 2007 4 3 371 386 2-s2.0-34250783638 10.1016/j.nurt.2007.05.006 (Pubitemid 46962416)
192. Cass W. A., Grondin R., Andersen A. H., Zhang Z., Hardy P. A., Hussey-Andersen L. K., Rayens W. S., Gerhardt G. A., Gash D. M., Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys. Neurobiology of Aging 2007 28 2 258 271 2-s2.0-33845387875 10.1016/j.neurobiolaging.2005.12.010 (Pubitemid 44894635)
193. Hozumi I., Hasegawa T., Honda A., Ozawa K., Hayashi Y., Hashimoto K., Yamada M., Koumura A., Sakurai T., Kimura A., Tanaka Y., Satoh M., Inuzuka T., Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. Journal of the Neurological Sciences 2011 303 1-2 95 99 2-s2.0-79952816599 10.1016/j.jns.2011.01.003
194. Kozlowski H., Luczkowski M., Remelli M., Valensin D., Copper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases). Coordination Chemistry Reviews 2012 256 2129 2141 10.1016/j.ccr.2012.03.013
195. Moran L. B., Duke D. C., Deprez M., Dexter D. T., Pearce R. K. B., Graeber M. B., Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics 2006 7 1 1 11 2-s2.0-33644658492 10.1007/s10048-005-0020-2 (Pubitemid 43327678)
196. Zhang Y., James M., Middleton F. A., Davis R. L., Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. American Journal of Medical Genetics. Part B 2005 137 1 5 16 2-s2.0-23044502947 10.1002/ajmg.b.30195 (Pubitemid 41076605)
197. Lesnick T. G., Papapetropoulos S., Mash D. C., Ffrench-Mullen J., Shehadeh L., de Andrade M., Henley J. R., Rocca W. A., Ahlskog J. E., Maraganore D. M., A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS genetics 2007 3 6 e98 2-s2.0-38449117932 10.1371/journal.pgen.0030098 (Pubitemid 47015858)
198. Liu Y., Guan W., Ren G. G., Yang Z., The possible mechanism of silver nanoparticle impact on hippocampal synaptic plasticity and spatial cognition in rats. Toxicology Letters 2012 209 3 227 231 10.1016/j.toxlet.2012.01.001
199. Dziendzikowska K., Gromadzka-Ostrowska J., Lankoff A., Oczkowski M., Krawczynska A., Chwastowska J., Sadowska-Bratek M., Chajduk E., Wojewodzka M., Dusinska M., Kruszewski M., Time-dependent biodistribution and excretion of silver nanoparticles in male Wistar rats. 2012 32 11 920 928
200. Asare N., Instanes C., Sandberg W. J., Refsnes M., Schwarze P., Kruszewski M., Brunborg G., Cytotoxic and genotoxic effects of silver nanoparticles in testicular cells. Toxicology 2012 291 1-3 65 72 10.1016/j.tox.2011.10.022
201. Lankoff A., Sandberg W. J., Wegierek-Ciuk A., Lisowska H., Refsnes M., Sartowska B., Schwarze P. E., Meczynska-Wielgosz S., Wojewodzka M., Kruszewski M., The effect of agglomeration state of silver and titanium dioxide nanoparticles on cellular response of HepG2, A549 and THP-1 cells. Toxicology Letters 2012 208 3 197 213 10.1016/j.toxlet.2011.11.006
202. Hadrup N., Loeschner K., Mortensen A., Sharma A. K., Qvortrup K., Larsen E. H., Lam H. R., The similar neurotoxic effects of nanoparticulate and ionic silver in vivo and in vitro. Neurotoxicology 2012 33 3 416 423 10.1016/j.neuro.2012.04.008
203. Little J. W., Doyle T., Salvemini D., Reactive nitroxidative species and nociceptive processing: determining the roles for nitric oxide, superoxide, and peroxynitrite in pain. Amino Acids 2012 42 1 75 94 2-s2.0-77953344323 10.1007/s00726-010-0633-0
204. Xue Y., Wu J., Sun J., Four types of inorganic nanoparticles stimulate the inflammatory reaction in brain microglia and damage neurons in vitro. Toxicology Letters 2012 214 2 91 98 10.1016/j.toxlet.2012.08.009
205. Elder A., Gelein R., Silva V., Feikert T., Opanashuk L., Carter J., Potter R., Maynard A., Ito Y., Finkelstein J., Oberder G., Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environmental Health Perspectives 2006 114 8 1172 1178 2-s2.0-33746902053 10.1289/ehp.9030 (Pubitemid 44184673)
206. Lucchini R. G., Dorman D. C., Elder A., Veronesi B., Neurological impacts from inhalation of pollutants and the nose-brain connection. Neurotoxicology 2012 33 4 838 841 10.1016/j.neuro.2011.12.001
207. Calderon-Garciduenas L., Franco-Lira M., Henriquez-Roldan C., Urban air pollution: influences on olfactory function and pathology in exposed children and young adults. Experimental and Toxicologic Pathology 2010 62 1 91 102 2-s2.0-71849109449 10.1016/j.etp.2009.02.117
208. Hawkes C., Olfaction in neurodegenerative disorder. Movement Disorders 2003 18 4 364 372 2-s2.0-0038408929 10.1002/mds.10379 (Pubitemid 36527276)
209. Kranick S. M., Duda J. E., Olfactory dysfunction in Parkinson's disease. NeuroSignals 2007 16 1 35 40 2-s2.0-37349030191 10.1159/000109757